3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Endocrine
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Breast Diseases
1
Advanced Metastatic Breast Cancer
1
Interventions
Carboplatin
36
Cisplatin
32
pembrolizumab
30
Paclitaxel
29
Pemetrexed
22
Gemcitabine
21
Nivolumab
19
Dexamethasone
17
Rituximab
16
Fluorouracil
13
Docetaxel
13
durvalumab
12
Ipilimumab
12
Capecitabine
12
Cyclophosphamide
11
atezolizumab
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Trastuzumab
9
Lenalidomide
9
Doxorubicin
9
Cytarabine
9
Bevacizumab
9
daratumumab
8
Oxaliplatin
8
Bortezomib
8
Vinorelbine
7
Prednisone
7
Leucovorin
7
venetoclax
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
ribociclib
×
Clear all
NCT03701334
2026-04-01
NATALEE
Novartis
Phase 3
Active not recruiting
5,101 enrolled
1 FDA
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA